Introduction {#sec1}
============

The direct oxidative C--H bond functionalization has emerged as an effective tool for the construction of carbon--carbon and carbon--heteroatom bonds.^[@ref1]^ Transition metals play vital role in oxidative C--H coupling reactions.^[@ref2]^ Metal-free organic syntheses for the construction of C--C and C--X bonds are also popular.^[@ref3]^ Molecular iodine is a popular catalyst in various organic transformations owing to its easy availability and inexpensive, nontoxic, eco-friendly, and nonmetallic nature.^[@ref4]^ Additionally, molecular iodine has superfluous advantages as it has the lowest dissociation energy, no radioactivity, and a moderate redox potential.^[@ref5]^ In 2010, Li et al. reported I~2~-mediated oxidative cyclization of enamines via iodide intermediates.^[@ref6]^

Nitrogen-containing heterocycles are ubiquitous scaffolds in numerous natural products, biomolecules, and organic materials.^[@ref7]^ Benzo\[4,5\]imidazo\[1,2-*c*\]quinazoline is a trinitrogen heterocycle that hosts both the fused structure of benzimidazole and quinazoline via a shared bond.^[@ref8]^ The combination of benzimidazole and quinazoline frameworks, benzimidazoquinazoline derivatives, are valuable substrates with different biological activities as shown in [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"} and benzoimidazo\[1,2-*c*\]quinazoline derivatives exhibit wide spectrum of therapeutic activities such as antimicrobial,^[@ref9]^ antitumor,^[@ref10]^ anticancer,^[@ref11]^ antiviral,^[@ref12]^ anti-inflammatory,^[@ref13]^ and anticonvulsants.^[@ref14]^ Due to the remarkable importance of these molecules, we planned to propose a new method for construction of benzoimidazo\[1,2-*c*\]quinazoline derivatives. A number of synthetic methodologies for construction of the compounds containing this core structure were reported. Hulme et al.^[@ref15]^ reported a cesium carbonate-promoted three-component reaction, CuI-catalyzed Ullmann N-arylation.^[@ref16]^ Fu et al. reported a copper-catalyzed cascade synthesis of benzimidazoquinazoline derivatives under mild conditions ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}a).^[@ref17]^ Fu et al. developed a general method for the synthesis of benzoimidazo\[1,2-*c*\] quinazolines via copper-catalyzed reactions of substituted 2-(2-halophenyl)-1*H*-benzo\[*d*\]imidazoles with α-amino acids ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}b).^[@ref18]^ Later, Koutentis and co-workers reported Cu- and Pd-catalyzed oxidative and nonoxidative C--N coupling reactions to give the corresponding products in high yields ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}c).^[@ref19]^ Recently, Sarada et al. established a nickel-catalyzed aerobic oxidative isocyanide insertion reaction for the synthesis of a novel benzimidazoquinazolines via sequential double annulation cascade protocol ([Schemes [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}d and [[2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}).^[@ref20]^ All of the above reports suffer from drawbacks such as the use of prefunctionalized starting materials, harsh reaction conditions, longer reaction time, and metal catalyst. Therefore, the development of new approaches to the synthesis of benzimidazoquinazolines using simpler and more readily available starting materials under milder conditions is still highly desirable.

![Biologically important benzoimidazo\[1,2-*c*\]quinazolines.](ao-2018-00067a_0007){#fig1}

![Recent Approaches for the Construction of Benzoimidazo\[1, 2-*c*\]quinazolines](ao-2018-00067a_0009){#sch1}

![Synthesis of Benzoimidazo Quinazolinones](ao-2018-00067a_0005){#sch2}

In continuation of our ongoing research to develope new routes for the construction of various heterocyclic systems,^[@ref21]^ we investigated the reaction of 4-methylacetophenone **1b** with 2-(1*H*-benzo\[*d*\]imidazol-2-yl) aniline **2** as model substrates for the present study. The reaction has been carried out under various reaction conditions, as depicted in [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}. On treatment of **1b** with **2** and an equivalent of iodine as the catalyst in *N*,*N*-dimethylacetamide (DMA) at 110 °C for 6 h, the desired product **3b** was not formed ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 1). Further optimization was done by the use of other common organic solvents including *N*,*N*-dimethylformamide (DMF), toluene, *N*-methylpyrrolidone (NMP), acetonitrile, and DMSO ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entries 2--6), and DMSO has been proved to be the best solvent. Next, we tried the reaction in the absence of the catalyst in dimethyl sulfoxide (DMSO), but there was no product obtained even after long reaction time. Hence, additional optimization experiments were performed in the presence of various iodides such KI, NIS, TBAI, and NH~4~I in DMSO at 110 °C for 6 h. However, the desired product was not obtained ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entries 8--11). Further increase in the amount of iodine did not lead to significant differences in the yield ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 12). Further, we optimized the reaction in the presence of different stoichiometric amounts of iodine in DMSO ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entries 13--17), the corresponding product was obtained in 78, 80, 83, and 75% yield, respectively. The combination of iodine (20 mol %) and DMSO was found to be efficient for this transformation ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 16). So, all of the reactions were carried out under this reaction conditions.

###### Optimization of Reaction Conditions[a](#t1fn1){ref-type="table-fn"}

![](ao-2018-00067a_0003){#fx1}

  entry   catalyst (equiv)   solvent                                temp     yield (%)[b](#t1fn2){ref-type="table-fn"}
  ------- ------------------ -------------------------------------- -------- -------------------------------------------
  1       I~2~ (1.0)         DMA[c](#t1fn3){ref-type="table-fn"}    110 °C   NR
  2       I~2~ (1.0)         DMF[c](#t1fn3){ref-type="table-fn"}    110 °C   NR
  3       I~2~ (1.0)         toluene                                110 °C   NR
  4       I~2~ (1.0)         NMP[c](#t1fn3){ref-type="table-fn"}    reflux   NR
  5       I~2~ (1.0)         CH~3~CN                                reflux   NR
  6       I~2~ (1.0)         DMSO[c](#t1fn3){ref-type="table-fn"}   110 °C   78
  7       −                  DMSO[c](#t1fn3){ref-type="table-fn"}   110 °C   NR
  8       KI (1.0)           DMSO                                   110 °C   NR
  9       NIS (1.0)          DMSO[c](#t1fn3){ref-type="table-fn"}   110 °C   NR
  10      TBAI (1.0)         DMSO[c](#t1fn3){ref-type="table-fn"}   110 °C   NR
  11      NH~4~I (1.0)       DMSO[c](#t1fn3){ref-type="table-fn"}   110 °C   NR
  12      I~2~ (1.2)         DMSO[c](#t1fn3){ref-type="table-fn"}   110 °C   73
  13      I~2~ (0.8)         DMSO[c](#t1fn3){ref-type="table-fn"}   110 °C   78
  14      I~2~ (0.6)         DMSO[c](#t1fn3){ref-type="table-fn"}   110 °C   80
  15      I~2~ (0.4)         DMSO[c](#t1fn3){ref-type="table-fn"}   110 °C   80
  16      I~2~ (0.2)         DMSO[c](#t1fn3){ref-type="table-fn"}   110 °C   83
  17      I~2~ (0.1)         DMSO[c](#t1fn3){ref-type="table-fn"}   110 °C   75

Reaction conditions: **1b** (1.0 equiv) additive and solvent (2 mL) are heated in a sealed tube at 110 °C for 6 h and then **2** (1.0 equiv) is added.

Yield of the isolated product.

DMF = *N*,*N*-dimethylformamide, DMA = *N*,*N*-dimethylacetamide, NMP = *N*-methylpyrrolidone, DMSO = dimethyl sulfoxide.

With the optimized reaction conditions in hand, we then investigated the substrate scope of the aryl methyl ketones, as shown in [Scheme [3](#sch3){ref-type="scheme"}](#sch3){ref-type="scheme"}. Aryl methyl ketones bearing electron-donating and electron-withdrawing substituents were successfully converted directly into the corresponding products in moderate to good yields (73--83%; **3a**--**3h**). Moreover, sterically hindered acetyl naphthalene has only little influence on the reaction efficiency (73--83%; **3j** and **3k**). Notably, heterocyclic methyl ketones also participated in the reaction affording the corresponding products **3n**--**3p** in 59--62% yields, respectively.

![Substrate Scope of the Transformation^,^\
Reaction conditions: **1** (1.0 equiv), **2** (1.0 equiv), and I~2~ (0.2 equiv) in DMSO (2 mL) at 110 °C.\
Isolated yield.](ao-2018-00067a_0006){#sch3}

To have a better understanding of the reaction mechanism, a series of control experiments were performed ([Scheme [4](#sch4){ref-type="scheme"}](#sch4){ref-type="scheme"}). The reaction of acetophenone **1a** with **2** in presence of I~2~ affords **3a** in good yields ([Scheme [4](#sch4){ref-type="scheme"}](#sch4){ref-type="scheme"}a). Next, the reaction was carried out α-iodoketone **1ab** with DMSO and phenylglyoxal was obtained in 81% yield ([Scheme [4](#sch4){ref-type="scheme"}](#sch4){ref-type="scheme"}b). Subsequently, the reaction of α-iodoketone **1ab** with 2-(1*H*-benzo\[*d*\]imidazol-2-yl) aniline **2** was found to be effective and the product **3a** was obtained in 69% yield ([Scheme [4](#sch4){ref-type="scheme"}](#sch4){ref-type="scheme"}c). When the acetophenone was replaced with phenylglyoxal **1ac**, the desired product was obtained in 75% yield ([Scheme [4](#sch4){ref-type="scheme"}](#sch4){ref-type="scheme"}d). These results confirmed that α-iodoketone **1ab** is a possible precursor of α-ketoaldehyde **1ac**. Moreover, the results also indicated that phenacyl iodide **1ab** and phenylglyoxal **1ac** are the key intermediates in the transformation. Finally, the radical trapping experiments were tested ([Scheme [4](#sch4){ref-type="scheme"}](#sch4){ref-type="scheme"}e). 2,2,6,6-Tetramethylpiperidinyloxy (TEMPO) was used as a radical scavenger. In the presence of TEMPO, desired product was observed in good yield (71%) and this result shows that radical intermediates were not involved in this reaction.

![Investigation Into the Reaction Mechanism](ao-2018-00067a_0001){#sch4}

Structural elucidation of benzoimidazoquinazoline was accomplished by using one-dimensional and two-dimensional, as described for **3b**. In the ^1^H NMR spectrum (see the [SI](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b00067/suppl_file/ao8b00067_si_001.pdf)) of **3b**, the methyl protons appear as a sharp singlet at 2.43 ppm, which gives C--H COSY correlation with the carbon at 22.5 ppm and β-hydroxy β-methylbutyrate (HMB) correlation with the carbons at 130.2 and 145.7 ppm ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}). The two-proton signal appears as a doublet at 8.09 ppm (*J* = 7.8 Hz), which gives C--H COSY correlation with the carbon at 130.2 ppm and HMB correlation with the carbons at 145.7 and 191.9 ppm.

![^1^H, ^13^C chemical shifts and HMB correlations of **3b**.](ao-2018-00067a_0008){#fig2}

The structure of the product **3** was confirmed by an electrospray ionization mass spectroscopy (ESI-MS). On the basis of the above results and literature reports, a plausible mechanism for the formation of **3** is shown in [Scheme [5](#sch5){ref-type="scheme"}](#sch5){ref-type="scheme"}.^[@cit5b]^ First, the reaction of **1** with I~2~ results in the formation of α-iodoketone **1ab**. Subsequently, oxidation of **1ab** with DMSO at 110 °C gives arylglyoxal **1ac**, with the removal of dimethyl sulfide. The next step is the reaction between arylglyoxal **1ac** and **2** that generates an iminium ion intermediate **2a**. The intermediate **2a** is quickly converted to the desired product **3**.

![Plausible Mechanism for the Formation of Benzoimidazoquinazoline Derivatives](ao-2018-00067a_0002){#sch5}

Conclusions {#sec2}
===========

We have developed a simple, novel, and efficient method for the synthesis of benzoimidazoquinazoline by iodine-catalyzed oxidative C--H amination of aryl methyl ketones and 2-(1*H*-benzo\[*d*\]imidazol-2-yl) aniline. The initial studies of the mechanism suggest that this reaction could have occurred through a self-sequenced iodination/Kornblum oxidation/C--H amination and intramolecular cyclization reactions.

General Methods {#sec2.1}
---------------

The melting points were measured in open capillary tubes and were uncorrected. The ^1^H and ^13^C NMR spectra were recorded on a Bruker (Avance) 300 MHz NMR instrument using TMS as internal standard either CDCl~3~ or DMSO-*d*~6~ as solvent. Chemical shifts are given in parts per million (δ-scale) and the coupling constants are given in hertz (Hz). Silica gel-G plates (Merck) were used for thin layer chromatography (TLC) analysis with a mixture of petroleum ether (60--80 °C) and ethyl acetate as eluent. High-resolution mass spectra were recorded on a Waters Q-TOF micromass spectrometer using ESI mode.

General Experimental Procedure for **3** Benzo\[4,5\]imidazo\[1,2-*c*\]quinazolin-6-yl(phenyl)methanone (**3a**--**3n**) {#sec2.2}
------------------------------------------------------------------------------------------------------------------------

A mixture of aryl methyl ketone **1** (100 mg, 0.83 mmol) and 2-(1*H*-benzo\[*d*\]imidazol-2-yl) aniline **2** (174 mg, 0.83 mmol) was taken in a 10 mL round-bottom flask in DMSO and 2 mL of I~2~ (42 mg, 20 mol %) was added and reaction mixture was refluxed at 110 °C for 6 h. The reaction was monitored by TLC using *n*-hexane/ethyl acetate mixture (3:2) as eluent. After the completion of the reaction, the mixture was poured into ice water, worked up with sodium thiosulphate, and extracted with ethyl acetate. The organic layer was collected, dried on anhydrous sodium sulfate, and the solvent was evaporated on a rotary evaporator to get the crude product. The crude product was purified by silica gel column using 30:70 *n*-hexane/ethyl acetate.

### Benzo\[4,5\]imidazo\[1,2-*c*\]quinazolin-6-yl(phenyl)methanone (**3a**) {#sec2.2.1}

Yellow solid (215 mg, 80%); mp 222--224 °C; ^1^H NMR (300 MHz, DMSO-*d*~6~) δ 8.18 (d, *J* = 7.9 Hz, 1H), 8.03 (d, *J* = 7.7 Hz, 2H), 7.80 (d, *J* = 7.8 Hz, 1H), 7.61 (d, *J* = 7.1 Hz, 1H), 7.56--7.44 (m, 2H), 7.29--7.14 (m, 3H), 7.00 (s, 1H), 6.93 (t, *J* = 7.1 Hz, 1H), 6.76 (d, *J* = 8.1 Hz, 1H), 6.28 (s, 1H); ^13^C NMR (75 MHz, CDCl~3~ with DMSO-*d*~6~) δ 190.1, 147.4, 143.0, 140.0, 133.2, 132.1, 130.6, 128.1, 127.4, 124.1, 121.6, 118.7, 118.0, 115.0, 112.3, 108.2.

### Benzo\[4,5\]imidazo\[1,2-*c*\]quinazolin-6-yl(*p*-tolyl)methanone (**3b**) {#sec2.2.2}

Yellow solid (209 mg, 83%); mp 226--228 °C; ^1^H NMR (300 MHz, DMSO-*d*~6~) δ 8.13 (d, *J* = 7.5 Hz, 1H), 7.91 (d, *J* = 8.0 Hz, 2H), 7.77 (d, *J* = 7.8 Hz, 1H), 7.28--7.19 (m, 3H), 7.16--7.10 (m, 2H), 6.99 (d, *J* = 7.7 Hz, 1H), 6.88 (dd, *J* = 9.8, 5.1 Hz, 1H), 6.74 (d, *J* = 7.9 Hz, 1H), 6.52 (d, *J* = 3.4 Hz, 1H), 2.39 (s, 3H); ^13^C NMR (75 MHz, CDCl~3~ with DMSO-*d*~6~) δ 191.9, 149.0, 145.8, 144.7, 142.1, 134.0, 132.2, 131.2, 130.4, 130.2, 125.4, 123.1, 122.9, 119.7, 119.5, 116.2, 113.8, 110.5, 22.1; HRMS (*m*/*z*) (ESI): calcd for C~22~H~15~N~3~O 337.1215; found 337.1219 \[M + H\]^+^.

### Benzo\[4,5\]imidazo\[1,2-*c*\]quinazolin-6-yl(4-methoxyphenyl)methanone (**3c**) {#sec2.2.3}

Yellow solid (191 mg, 81%); mp 194--196 °C; ^1^H NMR (300 MHz, DMSO-*d*~6~) δ 8.11 (d, *J* = 8.8 Hz, 2H), 8.06 (d, *J* = 7.8 Hz, 1H), 7.72 (d, *J* = 7.8 Hz, 1H), 7.35 (d, *J* = 3.5 Hz, 1H), 7.29--7.12 (m, 5H), 7.00 (d, *J* = 8.8 Hz, 2H), 6.83 (dd, *J* = 15.2, 7.8 Hz, 2H), 3.87 (s, 3H); ^13^C NMR (75 MHz, CDCl~3~ with DMSO-*d*~6~) δ 189.3, 164.0, 148.2, 143.8, 141.1, 132.9, 131.4, 131.2, 125.6, 124.7, 122.4, 122.2, 119.1, 118.7, 115.4, 114.1, 112.9, 108.9, 55.5; HRMS (*m*/*z*) (ESI): calcd for C~22~H~15~N~3~O~2~ 353.1164; found 353.1169 \[M + H\]^+^.

### Benzo\[4,5\]imidazo\[1,2-*c*\]quinazolin-6-yl(3-methoxyphenyl)methanone (**3d**) {#sec2.2.4}

Yellow solid (188 mg, 80%); mp 183--185 °C; ^1^H NMR (300 MHz, DMSO-*d*~6~) δ 8.16 (d, *J* = 7.6 Hz, 1H), 7.89 (d, *J* = 3.7 Hz, 1H), 7.78 (d, *J* = 7.8 Hz, 2H), 7.70 (d, *J* = 4.9 Hz, 1H), 7.29--7.18 (m, 5H), 7.15--7.08 (m, 1H), 6.96--6.87 (m, 2H), 6.85--6.70 (m, 3H) 3.86 (s, 1H); ^13^C NMR (75 MHz, CDCl~3~) δ 188.4, 163.1, 147.2, 142.9, 140.2, 132.0, 130.5, 130.3, 124.7, 123.8, 121.5, 121.3, 118.2, 117.8, 114.5, 113.2, 112.0, 108.0, 54.5.

### Benzo\[4,5\]imidazo\[1,2-*c*\]quinazolin-6-yl(4-hydroxyphenyl)methanone (**3e**) {#sec2.2.5}

Yellow solid (194 mg, 78%); mp 188--190 °C; ^1^H NMR (300 MHz, DMSO-*d*~6~) δ 10.38 (s, 1H), 8.07--8.00 (m, 2H), 7.75--7.70 (m, 1H), 7.25--7.15 (m, 5H), 6.94 (d, *J* = 8.7 Hz, 2H), 6.84 (dd, *J* = 15.9, 7.5 Hz, 2H); ^13^C NMR (75 MHz, CDCl~3~ with DMSO-*d*~6~) δ 188.3, 162.4, 147.3, 143.0, 140.5, 132.2, 130.8, 130.4, 123.9, 123.6, 121.5, 121.4, 118.2, 117.9, 115.0, 114.6, 112.2, 108.1.

### Benzo\[4,5\]imidazo\[1,2-*c*\]quinazolin-6-yl(3,4-methoxyphenyl)methanone (**3f**) {#sec2.2.6}

Yellow solid (159 mg, 75%); mp 189--191 °C; ^1^H NMR (300 MHz, CDCl~3~ with DMSO-*d*~6~) δ 8.03 (d, *J* = 7.1 Hz, 1H), 7.93 (d, *J* = 8.5 Hz, 1H), 7.70 (d, *J* = 7.9 Hz, 1H), 7.54 (s, 1H), 7.43 (broad, s, 1H), 7.35 (d, *J* = 7.8 Hz, 1H), 7.23--7.12 (m, 3H), 7.05 (d, *J* = 8.5 Hz, 1H), 6.83 (t, *J* = 7.4 Hz, 2H), 3.93 (s, 3H), 3.85 (s, 3H); ^13^C NMR (75 MHz, CDCl~3~ with DMSO-*d*~6~) δ 188.4, 152.7, 147.7, 147.0, 142.5, 140.1, 131.7, 130.0, 124.4, 123.4, 122.9, 121.1, 120.9, 117.6, 117.4, 114.1, 111.5, 109.9, 109.5, 108.0, 54.7, 54.5 HRMS (*m*/*z*) (ESI): calcd for C~23~H~17~N~3~O~3~ 383.1270; found 383.1274 \[M + H\]^+^.

### Benzo\[4,5\]imidazo\[1,2-*c*\]quinazolin-6-yl(4-chlorophenyl)methanone (**3g**) {#sec2.2.7}

Yellow solid (151 mg, 71%); mp 198--200 °C; ^1^H NMR (300 MHz, CDCl~3~) δ 8.10 (d, *J* = 7.5 Hz, 1H), 7.96 (d, *J* = 8.4 Hz, 2H), 7.75 (d, *J* = 7.8 Hz, 1H), 7.61 (d, *J* = 8.4 Hz, 2H), 7.24--7.18 (m, 5H), 6.88 (t, *J* = 7.5 Hz, 1H), 6.80 (d, *J* = 8.1 Hz, 1H); ^13^C NMR (75 MHz, CDCl~3~) δ 189.4, 147.4, 143.4, 140.0, 132.3, 131.4, 131.2, 130.8, 130.0, 124.4, 122.0, 121.9, 119.2, 118.4, 115.3, 112.7, 108.1; HRMS (*m*/*z*) (ESI): calcd for C~21~H~12~ClN~3~O 357.0669; found 357.0676 \[M + H\]^+^.

### Benzo\[4,5\]imidazo\[1,2-*c*\]quinazolin-6-yl(4-bromophenyl)methanone (**3h**) {#sec2.2.8}

Yellow solid (144 mg, 72%); mp 200--202 °C; ^1^H NMR (300 MHz, CDCl~3~ with DMSO-*d*~6~) δ 8.14 (d, *J* = 7.8 Hz, 1H), 7.92 (d, *J* = 8.6 Hz, 2H), 7.77 (d, *J* = 7.8 Hz, 1H), 7.60 (d, *J* = 8.5 Hz, 2H), 7.22 (ddd, *J* = 17.1, 10.6, 4.2 Hz, 4H), 7.01 (d, *J* = 4.3 Hz, 1H), 6.90 (dd, *J* = 9.2, 5.8 Hz, 2H), 6.79 (d, *J* = 7.9 Hz, 1H); ^13^C NMR (75 MHz, CDCl~3~ with DMSO-*d*~6~) δ 190.5, 148.2, 144.4, 140.8, 133.3, 132.5, 132.2, 131.8, 130.9, 129.6, 125.6, 123.1, 123.0, 120.5, 119.6, 116.3, 113.8, 109.0; HRMS (*m*/*z*) (ESI): calcd for C~21~H~12~BrN~3~O 401.0164; found: 401.0172 \[M + H\]^+^.

### Benzo\[4,5\]imidazo\[1,2-*c*\]quinazolin-6-yl(3,4-dichlorophenyl)methanone (**3i**) {#sec2.2.9}

Yellow solid (140 mg, 68%); mp 192--194 °C; ^1^H NMR (300 MHz, CDCl~3~ with DMSO-*d*~6~) δ 8.28 (d, *J* = 1.8 Hz, 1H), 8.09 (d, *J* = 7.8 Hz, 1H), 7.95 (dd, *J* = 8.4, 1.9 Hz, 1H), 7.75 (d, *J* = 7.8 Hz, 1H), 7.58 (d, *J* = 8.4 Hz, 1H), 7.37 (d, *J* = 4.5 Hz, 1H), 7.29--7.17 (m, 4H), 6.92--6.77 (m, 2H); ^13^C NMR (75 MHz, CDCl~3~ with DMSO-*d*~6~) δ 194.3, 153.3, 149.2, 145.7, 143.4, 138.3, 138.1, 133.6, 130.3, 127.9, 127.8, 125.2, 124.3, 121.3, 118.8, 114.2; HRMS (*m*/*z*) (ESI): calcd for C~21~H~11~Cl~2~N~3~O 391.0279; found: 391.0279 \[M^+^\].

### Benzo\[4,5\]imidazo\[1,2-*c*\]quinazolin-6-yl(naphthalen-2-yl)methanone (**3j**) {#sec2.2.10}

Yellow solid (138 mg, 63%); mp 186--188 °C; ^1^H NMR (300 MHz, DMSO-*d*~6~) δ 8.25 (d, *J* = 8.1 Hz, 1H), 8.19--8.00 (m, 3H), 7.90 (d, *J* = 8.5 Hz, 2H), 7.78 (d, *J* = 7.5 Hz, 1H), 7.66--7.47 (m, 3H), 7.38--7.27 (m, 1H), 7.22 (dd, *J* = 17.7, 10.8 Hz, 2H), 7.07--6.93 (m, 1H), 6.82--6.14 (m, 1H), 6.63 (d, *J* = 8.4 Hz, 1H); ^13^C NMR (75 MHz, DMSO-*d*~6~) δ 194.6, 143.3, 141.0, 132.9, 132.6, 131.5, 131.3, 130.8, 129.8, 128.0, 127.3, 126.0, 125.3, 124.7, 124.2, 124.0, 123.4, 122.3, 121.8, 121.6, 118.9, 118.5, 118.1, 115.6, 114.8, 112.5, 109.3. HRMS (*m*/*z*) (ESI): calcd for C~25~H~15~N~3~O 373.1215; found: 373.1216 \[M + H\]^+^.

### \[1,1′-Biphenyl\]-4-yl(benzo\[4,5\]imidazo\[1,2-*c*\]quinazolin-6-yl)methanone (**3k**) {#sec2.2.11}

Yellow solid (136 mg, 65%); mp 230--232 °C; ^1^H NMR (300 MHz, CDCl~3~) δ 8.21 (d, *J* = 8.1 Hz, 2H), 8.09 (d, *J* = 7.0 Hz, 1H), 7.75 (dd, *J* = 7.4, 2.9 Hz, 3H), 7.65 (d, *J* = 6.8 Hz, 2H), 7.54--7.38 (m, 5H), 7.35--7.28 (m, 2H), 7.27--7.15 (m, 3H), 6.86 (dd, *J* = 15.5, 7.8 Hz, 2H). ^13^C NMR (75 MHz, CDCl~3~ with DMSO-*d*~6~) δ 195.7, 153.5, 151.5, 149.3, 146.3, 144.4, 138.4, 137.1, 136.6, 135.0, 134.2, 133.7, 132.5, 132.3, 130.2, 127.8, 127.7, 124.7, 124.2, 121.0, 118.5, 114.3; HRMS (*m*/*z*) (ESI): calcd for C~27~H~17~N~3~NaO 422.1269; found: 422.1471 \[M + Na\]^+^.

### Benzo\[4,5\]imidazo\[1,2-*c*\]quinazolin-6-yl(5-bromothiophen-2-yl)methanone (**3l**) {#sec2.2.12}

Yellow solid (116 mg, 58%); mp 218--220 °C; ^1^H NMR (300 MHz, DMSO-*d*~6~) δ 8.14 (d, *J* = 6.8 Hz, 1H), 7.78 (d, *J* = 7.9 Hz, 1H), 7.53 (d, *J* = 4.1 Hz, 1H), 7.30--7.17 (m, 4H), 7.02 (d, *J* = 4.1 Hz, 1H), 6.93 (t, *J* = 7.5 Hz, 1H), 6.83 (d, *J* = 8.0 Hz, 1H), 6.63 (t, *J* = 4.0 Hz, 2H).^13^C NMR (75 MHz, CDCl~3~ with DMSO-*d*~6~) δ 185.1, 144.3, 140.7, 140.5, 134.5, 133.4, 132.9, 132.8, 125.6, 123.7, 120.1, 119.8, 116.3, 113.4, 109.3.

### Benzo\[4,5\]imidazo\[1,2-*c*\]quinazolin-6-yl(furan-2-yl)methanone (**3m**) {#sec2.2.13}

Yellow solid (165 mg, 56%); mp 194--196 °C; ^1^H NMR (300 MHz, CDCl~3~ with DMSO-*d*~6~) δ 8.06 (d, *J* = 7.2 Hz, 1H), 7.85--7.83 (m, 1H), 7.73 (d, *J* = 7.2 Hz, 1H), 7.32--7.19 (m, 5H), 6.99 (m, 3H), 6.68 (s, 1H); ^13^C NMR (75 MHz, CDCl~3~ with DMSO-*d*~6~) δ 179.7, 148.3, 147.4, 146.9, 143.1, 140.4, 132.1, 130.5, 123.9, 121.7, 121.6, 119.6, 118.4, 118.1, 114.5, 112.0, 108.1; HRMS (*m*/*z*) (ESI): calcd for C~19~H~11~N~3~O~2~ 313.0851; found 313.0862 \[M + H\]^+^.

### Benzo\[4,5\]imidazo\[1,2-*c*\]quinazolin-6-yl(pyridin-3-yl)methanone (**3n**) {#sec2.2.14}

Yellow solid (139 mg, 52%); mp 224--226 °C; ^1^H NMR (300 MHz, CDCl~3~ with DMSO-*d*~6~) δ 8.61 (d, *J* = 27.0 Hz, 2H), 8.13 (s, 1H), 7.67 (d, *J* = 51.6 Hz, 3H), 7.24 (s, 4 H), 6.87 (s, 5H); ^13^C NMR (75 MHz, CDCl~3~ with DMSO-*d*~6~) δ 185.8, 155.7, 153.0, 152.6, 149.3, 147.5, 140.5, 139.2, 137.9, 136.9, 130.4, 129.0, 127.8, 127.7, 124.5, 124.4, 120.4, 117.8, 115.0. HRMS (*m*/*z*) (ESI): calcd for C~20~H~12~N~4~O 324.1011; found 324.1016 \[M + H\]^+^.
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